Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe
Between 2000 and 2021, the European Medicines Agency (EMA) assigned the orphan designation to over 1,900 medicines. Due to their small target populations, leading to challenges regarding clinical trial recruitment, study design and little knowledge on the natural history of the disease, the overall...
Saved in:
Main Authors: | Carla J. Jonker (Author), Elisabeth Bakker (Author), Xavier Kurz (Author), Kelly Plueschke (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020
by: Elisabeth Bakker, et al.
Published: (2023) -
Use cases of registry‐based randomized controlled trials-A review of the registries' contributions and constraints
by: Nadine Kubesch, et al.
Published: (2024) -
Remodeling an existing rare disease registry to be used in regulatory context: Lessons learned and recommendations
by: Marina Mordenti, et al.
Published: (2022) -
De geesteswetenschappelijke carrousel Een nieuwe ronde in het debat over wetenschap, cultuur en politiek
by: Jonker, Ed
Published: (2006) -
Propositions for a counter-economy of assessment: Adventures in the assessment of creative arts in higher education
by: Francois Jonker
Published: (2023)